Dianthus Therapeutics Stock
Dianthus Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Marino Garcia
- Employees
- 92
- Market cap
- $4 B
- IPO
- 21/06/2018
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company in the healthcare sector headquartered in New York, USA. The company engages in the development of therapies for patients suffering from severe autoimmune diseases. Its research focus includes two primary clinical-stage candidates. The lead…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Dianthus Therapeutics stock: price history
1D
-3.3%
1W
-12.5%
1M
-29.7%
6M
-22.7%
YTD
+74.9%
1Y
+100.3%
2Y
+157.7%
5Y
-33.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~3% stronger price swings than usual
Dianthus Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Dianthus Therapeutics is a clinical-stage biotechnology company headquartered in New York that focuses on developing therapies to treat severe autoimmune diseases. Key drug candidates include the monoclonal antibody claseprubart and the bifunctional fusion protein DNTH212, which are designed to modulate specific biochemical pathways such as the complement system and interferon production. The company's revenue is currently generated entirely through licensing fees, which is characteristic of companies in the research and development phase.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Dianthus Therapeutics
Analyst assessment of Dianthus Therapeutics
PRICE TARGET LOW
US$120.00
CONSENSUS
US$132.60
MEDIAN
US$131.00
PRICE TARGET HIGH
US$158.00
1
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 15/10/2026
Dianthus Therapeutics stock metrics
P/E
-554.54
P/B
3.45
EV/EBITDA
-132.85
RETURN ON EQUITY
-4.3%
NET MARGIN
-6,598.6%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.1%
FLOAT SHARES
46,505,986
AVG. DAILY VOLUME (30D)
927,823
Insider transactions (SEC)
CARR EDWARD
CARR EDWARD
CARR EDWARD
CARR EDWARD
CARR EDWARD
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Dianthus Therapeutics stock
What does Dianthus Therapeutics do?
Dianthus Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Marino Garcia, the company employs around 92 people.
The IPO was on 21/06/2018; the stock trades on NASDAQ under the ticker DNTH.
What do analysts say about Dianthus Therapeutics stock?
11 analysts rate the stock, the consensus is Buy (as of 15/10/2026).
The average price target is US$132.60, ranging from US$120.00 to US$158.00, with a median of US$131.00.
This is an external assessment, not a statement by Market Jury.
When does Dianthus Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Dianthus Therapeutics pay a dividend?
No, Dianthus Therapeutics currently does not pay a dividend.
Which stocks are comparable to Dianthus Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Dianthus Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Dianthus Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.